University of Colorado Cancer Center, Anshutz Cancer Pavilion, PO Box 6510, Mail Stop F 703, Aurora, CO 80045, USA.
Immunotherapy. 2011 Jan;3(1):17-21. doi: 10.2217/imt.10.89.
In the USA, the incidence of cutaneous melanoma is increasing rapidly. It has been shown to be responsive to immune-stimulating drugs. Allovectin-7 allows the immune system to recognize metastatic melanoma lesions as foreign by incorporating a MHC class I complex into the tumor through direct injection. Once transfected, tumor biopsies have shown an increased presence of cytotoxic T lymphocytes in the tumor beds themselves. Phase I and II trials have shown local and systemic response to these tumors, with an excellent safety profile. Currently, a Phase III trial has completed enrollment and is set to determine the safety and efficacy of treatment in comparison with standard chemotherapy.
在美国，皮肤黑色素瘤的发病率正在迅速上升。现已证明，免疫刺激药物对此类肿瘤有效。Allovectin-7 通过直接将 MHC Ⅰ类复合物注入肿瘤，使免疫系统将转移性黑色素瘤病变识别为外来物。转染后，肿瘤活检显示肿瘤床中细胞毒性 T 淋巴细胞的存在增加。Ⅰ期和Ⅱ期临床试验显示，这些肿瘤对局部和全身治疗有反应，且安全性良好。目前，一项Ⅲ期临床试验已完成入组，旨在确定与标准化疗相比的治疗安全性和疗效。
